Instrument Inactif

Autres langues Cipher Pharmaceuticals Inc Other OTC

Actions

CA17253X1050

Produits pharmaceutiques

Autres langues

12/08	Cipher Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
11/08	Earnings Flash (CPH.TO) Cipher Pharmaceuticals Inc. Reports Q2 Revenue $12.1M, vs. FactSet Est of $13.6M
11/08	Cipher Pharmaceuticals Reports Second Quarter 2026 Results
31/07	Cipher Pharmaceuticals Schedules Q2 2026 Earnings Release and Conference Call
07/07	Cipher Pharmaceuticals Inks LOI With pCPA to List Severe Acne Treatment Epuris
06/07	Cipher Pharmaceuticals and the pan-Canadian Pharmaceutical Alliance (pCPA) Sign Letter of Intent for Public Drug Plan Coverage of Epuris®
06/07	Cipher Pharmaceuticals Inc. and Pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of Epuris
18/06	Cipher Pharmaceuticals Announces Results of Annual General Meeting of Shareholders
12/05	Canada research roundup-Altius Minerals, Cipher Pharmaceuticals, Suncor Energy
08/05	Cipher Pharmaceuticals : Quarterly Report Q1 2026
07/05	Earnings Flash (CPH.TO) Cipher Pharmaceuticals Reports Q1 Total Revenue US$12.5M, Up 4%; Adjusted EBITDA of $7.7M
07/05	Cipher Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	Cipher Pharmaceuticals Reports First Quarter Results
04/05	Cipher Pharmaceuticals Inc.'s Equity Buyback announced on May 1, 2025, has expired.
01/05	Cipher Pharmaceuticals Inc. announces an Equity Buyback for 1,490,343 shares, representing 5.87% of its issued share capital.
01/05	Cipher Pharmaceuticals Renews NCIB
01/05	Cipher Pharmaceuticals Announces Normal Course Issuer Bid
01/05	Cipher Pharmaceuticals Inc. authorizes a Buyback Plan.
29/04	Cipher Pharmaceuticals Schedules Q1 2026 Earnings Release and Conference Call
08/04	Cipher Pharmaceuticals : AIF 2025
07/04	Caryhealth and Cipher Pharmaceuticals US Llc Launch Direct-To-Patient Platform for Natroba
13/03	Cipher Pharmaceuticals Seeks Acquisitions
12/03	Cipher Pharmaceuticals : Annual Report 2025
12/03	Earnings Flash (CPH.TO) Cipher Pharmaceuticals Reports Q4 Revenue US$12.2M; Net income of $13.3M and $0.52 Per Share
12/03	Cipher Pharmaceuticals Reports Fourth Quarter Results and Full Year 2025 Record Revenue and Earnings